The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations

Introduction: EGFR exon 20 insertion mutations account for 5% to 10% of EGFR-mutated NSCLC. CLN-081 (formerly known as TAS6417), a novel covalent EGFR tyrosine kinase inhibitor, exhibits pan-mutation selective efficacy, including exon 20 insertions, in the clinical setting. Nevertheless, some patien...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Yosuke Kagawa, MD, Takuma Hayashida, MS, Jie Liu, BS, Shunta Mori, MD, Hiroki Izumi, MD, PhD, Shogo Kumagai, MD, PhD, Hibiki Udagawa, MD, PhD, Noboru Hattori, MD, PhD, Koichi Goto, MD, PhD, Susumu S. Kobayashi, MD, PhD
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2023-03-01
Saila:	JTO Clinical and Research Reports
Gaiak:	Non–small cell lung cancer EGFR CLN-081 Resistant mechanism C797S
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2666364323000012
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!